Studiul urmareste evaluarea eficacitatii si sigurantei administrarii inhalatorie de molgramostin la pacientii cu proteinoza alveolara pulmonara autoimuna.

Titlu Studiu

A Randomised, Double-Blind, Placebo-Controlled Multicentre Clinical Trial of Inhaled Molgramostim in Autoimmune Pulmonary AlveoLAr Proteinosis Patients “IMPALA”

Cod protocol: MOL-PAP-002

Numar EudraCT: –

Sponsor: Savara Inc.

Medicament de investigatie clinica: Molgramostin

Medicament de investigatie clinica comparator: Nu

Placebo: Da

International/National: International

Faza: II, III

Centre România

U.M. F Carol Davila, Pneumologie II, Insititul Marius Nasta, Bucuresti , Romania, 20021

Contact: Prof. Dumitru Mihaltan